Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial.
de la Fuente MI, Colman H, Rosenthal M, Van Tine BA, Levacic D, Walbert T, Gan HK, Vieito M, Milhem MM, Lipford K, Forsyth S, Guichard SM, Mikhailov Y, Sedkov A, Brevard J, Kelly PF, Mohamed H, Monga V.
de la Fuente MI, et al. Among authors: levacic d.
Neuro Oncol. 2023 Jan 5;25(1):146-156. doi: 10.1093/neuonc/noac139.
Neuro Oncol. 2023.
PMID: 35639513
Free PMC article.
Clinical Trial.